Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
foresiGHt trial of once-weekly lonapegsomatropin in adults with growth hormone deficiency
NL-OMON52023Phase 3Withdrawn
- Sponsor
- Ascendis Pharma
- Start
- Feb 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lonapegsomatropin in adult onset growth hormone deficiency (AGHD) (3 arms), sponsored by Ascendis Pharma. Primary endpoint: Primary efficacy endpoint. Planned start Feb 2021; status: withdrawn.
02
Drugs
lonapegsomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NL-OMON52023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52023.